Last reviewed · How we verify
2-Hydroxyflutamide
Anti-androgen receptor antagonist
Anti-androgen receptor antagonist Used for Prostate cancer.
At a glance
| Generic name | 2-Hydroxyflutamide |
|---|---|
| Also known as | Liproca Depot |
| Sponsor | Lidds AB |
| Drug class | Anti-androgen |
| Target | Androgen receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
2-Hydroxyflutamide acts as a non-steroidal anti-androgen that competitively inhibits the action of androgens, such as testosterone and dihydrotestosterone, at the androgen receptor.
Approved indications
- Prostate cancer
Common side effects
- Gynecomastia
- Hot flashes
- Impotence
Key clinical trials
- A Study to Evaluate the Safety, Tolerability and Efficacy of a Liproca® Depot Injection in Patients With Prostate Cancer (PHASE2)
- A Study of 2-hydroxyflutamide (Liproca Depot), Injected Into the Prostate in Patients With Localized Prostate Cancer (PHASE2)
- An Efficacy and Safety Study With Licroca Depot, a Controlled Release Product, Injected Into the Prostate (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 2-Hydroxyflutamide CI brief — competitive landscape report
- 2-Hydroxyflutamide updates RSS · CI watch RSS
- Lidds AB portfolio CI